Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7025888 | 0.82 | ALDH1A1 (0.39) | ALDH1A1CYP3A4HPGDEHMT2HSD17B10 | |
| SCHEMBL4057481 | 0.81 | KDM4E (0.37) | ALDH1A1CYP3A4HPGDEHMT2HSD17B10 | |
| SCHEMBL4435493 | 0.75 | L3MBTL1 (0.39) | ALDH1A1HPGDL3MBTL1 | |
| Hydrochloric Acid SCHEMBL25312951 | 0.73 | L3MBTL1 (0.38) | ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL9872779 | 0.67 | L3MBTL1 (0.37) | L3MBTL1 | |
| SCHEMBL23850269 | 0.66 | ALDH1A1 (0.38) | ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL28463998 | 0.66 | ALDH1A1 (0.48) | ALDH1A1CYP3A4HPGDEHMT2HSD17B10 | |
| SCHEMBL5002021 | 0.64 | ALDH1A1 (0.36) | ALDH1A1HPGD | |
| E927A SCHEMBL5599354 | 0.63 | ALDH1A1 (1.00) | ALDH1A1CYP3A4HPGDEHMT2HSD17B10 | |
| E927A SCHEMBL36851 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3043813-B2 | — | — | 2000-05-22 | — | — | JP | claimed |
| US-5874577-A | Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof | MEDICHEM RESEARCH, INC. (US) | 1999-02-23 | — | — | US | claimed |
| US-5847164-A | Method for the preparation of chromanone 7 | SARAWAK MEDICHEM PHARMACEUTICALS, INC. (US) | 1998-12-08 | — | — | US | claimed |
| EP-0775130-A1 | METHOD FOR THE PREPARATION OF (+/-)-CALANOLIDE A AND INTERMEDIATES THEREOF | MEDICHEM RESEARCH, INC. (US) | 1997-05-28 | — | — | EP | claimed |
| WO-1996004263-A1 | METHOD FOR THE PREPARATION OF (±)-CALANOLIDE A AND INTERMEDIATES THEREOF | MEDICHEM RESEARCH, INC. (US) | 1996-02-15 | — | — | WO | claimed |
| EP-1308448-A1 | Method for the preparation of chromanone | Sarawak Medichem Pharmaceuticals Inc. (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-0775130-B1 | METHOD FOR THE PREPARATION OF (+/-)-CALANOLIDE A AND INTERMEDIATES THEREOF | SARAWAK MEDICHEM PHARMACEUTICALS INC (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1143952-B1 | METHOD AND COMPOSITION FOR TREATING AND PREVENTING TUBERCULOSIS | SARAWAK MEDICHEM PHARMACEUTICALS INC (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020013478-A1 | Calanolide analogues and methods of their use | SARAWAK MEDICHEM PHARMACEUTICALS,INC. | 2002-01-31 | — | — | US | disclosed |
| US-6277879-B1 | VIRICIDES | SARAWAK MEDICHEM PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6268393-B1 | CALANOLIDES AND ANALOGUES THEREOF | SARAWAK MEDICHEM PHARMACEUTICALS | 2001-07-31 | — | — | US | disclosed |
| EP-1054007-A2 | Method for the preparation of (+/-)-calanolide A | MEDICHEM RESEARCH, INC. (US) | 2000-11-22 | — | — | EP | disclosed |
| US-5869324-A | Method for the preparation of (±)-calanolide A and intermediates thereof | SARAWAK MEDICHEM PHARMACEUTICALS, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| US-5859050-A | ADMINISTERING TO PREVENT OR TREAT A VIRAL INFECTION | SARAWAK MEDICHEM PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5847164-A | Method for the preparation of chromanone 7 | SARAWAK MEDICHEM PHARMACEUTICALS, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5840921-A | Method for the preparation of aldol product 7B | SARAWAK MEDICHEM PHARMACEUTICALS, INC. (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998038193-A1 | METHOD FOR THE PREPARATION OF (+)-CALANOLIDE A AND ANALOGUES THEREOF | MEDICHEM RESEARCH, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| EP-0775130-A1 | METHOD FOR THE PREPARATION OF (+/-)-CALANOLIDE A AND INTERMEDIATES THEREOF | MEDICHEM RESEARCH, INC. (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004263-A1 | METHOD FOR THE PREPARATION OF (±)-CALANOLIDE A AND INTERMEDIATES THEREOF | MEDICHEM RESEARCH, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| US-5055545-A | Paint primers; bonding strength; tire sidewalls; decoration | BRIDGESTONE/FIRESTONE, INC. (US) | 1991-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013478-A1 | Calanolide analogues and methods of their use | HAVCR2, ZC3HAV1, CYP51A1 | ALDH1A1 3786/4885CYP3A4 81/4885HPGD 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.